BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38752436)

  • 1. Proton pump inhibitors stabilize the expression of PD-L1 on cell membrane depending on the phosphorylation of GSK3β.
    Gao L; Liu Y; Liu J; Li J; Li H; Liu Y; Meng F; Du X; Gao Y; Li J; Qin FX
    Cancer Med; 2024 May; 13(10):e7083. PubMed ID: 38752436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers.
    Van Der Kraak L; Goel G; Ramanan K; Kaltenmeier C; Zhang L; Normolle DP; Freeman GJ; Tang D; Nason KS; Davison JM; Luketich JD; Dhupar R; Lotze MT
    J Immunother Cancer; 2016; 4():65. PubMed ID: 27777774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 4. SA-49, a novel aloperine derivative, induces MITF-dependent lysosomal degradation of PD-L1.
    Zhang N; Dou Y; Liu L; Zhang X; Liu X; Zeng Q; Liu Y; Yin M; Liu X; Deng H; Song D
    EBioMedicine; 2019 Feb; 40():151-162. PubMed ID: 30711516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (-)-4-
    Song G; Lu Y; Tang L; Li M; Yin J; Chen H; Ling J
    Immunopharmacol Immunotoxicol; 2021 Dec; 43(6):806-812. PubMed ID: 34694960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer.
    Wescott EC; Sun X; Gonzalez-Ericsson P; Hanna A; Taylor BC; Sanchez V; Bronzini J; Opalenik SR; Sanders ME; Wulfkuhle J; Gallagher RI; Gomez H; Isaacs C; Bharti V; Wilson JT; Ballinger TJ; Santa-Maria CA; Shah PD; Dees EC; Lehmann BD; Abramson VG; Hirst GL; Brown Swigart L; van ˈt Veer LJ; Esserman LJ; Petricoin EF; Pietenpol JA; Balko JM
    Cancer Res Commun; 2024 Apr; 4(4):1120-1134. PubMed ID: 38687247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of proton pump inhibitors on the clinical outcomes of PD-1/PD-L1 inhibitor in solid cancer patients.
    Wu B; Sun C; Sun X; Li X
    Medicine (Baltimore); 2022 Sep; 101(36):e30532. PubMed ID: 36086697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis.
    Lopes S; Pabst L; Dory A; Klotz M; Gourieux B; Michel B; Mascaux C
    Front Immunol; 2023; 14():1070076. PubMed ID: 36776847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma.
    Chen X; Wang K; Jiang S; Sun H; Che X; Zhang M; He J; Wen Y; Liao M; Li X; Zhou X; Song J; Ren X; Yi W; Yang J; Chen X; Yin M; Cheng Y
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35347072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of galectin-3 augments the antitumor efficacy of PD-L1 blockade in non-small-cell lung cancer.
    Zhang H; Liu P; Zhang Y; Han L; Hu Z; Cai Z; Cai J
    FEBS Open Bio; 2021 Mar; 11(3):911-920. PubMed ID: 33455075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpressed ITGA2 promotes malignant tumor aggression by up-regulating PD-L1 expression through the activation of the STAT3 signaling pathway.
    Ren D; Zhao J; Sun Y; Li D; Meng Z; Wang B; Fan P; Liu Z; Jin X; Wu H
    J Exp Clin Cancer Res; 2019 Dec; 38(1):485. PubMed ID: 31818309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solamargine improves the therapeutic efficacy of anti-PD-L1 in lung adenocarcinoma by inhibiting STAT1 activation.
    Liu Q; Xu M; Qiu M; Yu J; Wang Q; Zhou Y; Lin Q; Cai X; Yang L; Zhao H; Zhao C; Xie X
    Phytomedicine; 2024 Jun; 128():155538. PubMed ID: 38552432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 tumor-intrinsic signaling and its therapeutic implication in triple-negative breast cancer.
    Chen C; Li S; Xue J; Qi M; Liu X; Huang Y; Hu J; Dong H; Ling K
    JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33884962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting tumor-intrinsic PD-L1 suppresses the progression and aggressiveness of head and neck cancer by inhibiting GSK3β-dependent Snail degradation.
    Ahn CH; Oh KY; Jin B; Lee WW; Kim J; Kim HJ; Park DG; Swarup N; Chawla K; Ryu MH; Kim UK; Choi SJ; Yoon HJ; Hong SD; Shin JA; Cho SD
    Cell Oncol (Dordr); 2023 Apr; 46(2):267-282. PubMed ID: 36441378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer.
    Zhao S; Gao G; Li W; Li X; Zhao C; Jiang T; Jia Y; He Y; Li A; Su C; Ren S; Chen X; Zhou C
    Lung Cancer; 2019 Apr; 130():10-17. PubMed ID: 30885328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 mediates lung fibroblast to myofibroblast transition through Smad3 and β-catenin signaling pathways.
    Guo X; Sunil C; Adeyanju O; Parker A; Huang S; Ikebe M; Tucker TA; Idell S; Qian G
    Sci Rep; 2022 Feb; 12(1):3053. PubMed ID: 35197539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PPIs therapy has a negative impact on the clinical outcomes of advanced SCLC patients treated with PD-L1 inhibitors.
    Zhang S; Tian J; Wang X; Liu C
    BMC Pulm Med; 2023 Nov; 23(1):438. PubMed ID: 37951887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liposome Nanomedicine Based on Tumor Cell Lysate Mitigates the Progression of Lynch Syndrome-Associated Colon Cancer.
    Wang P; Zhong W; Huang Q; Zhu Y; Chen L; Ye K
    ACS Biomater Sci Eng; 2024 May; 10(5):3136-3147. PubMed ID: 38663028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.